Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Vaccinations01:51

Vaccinations

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Build-up and dephasing of Floquet-Bloch bands on subcycle timescales.

Nature·2023
Same author

Ultrafast electron dynamics in a topological surface state observed in two-dimensional momentum space.

Scientific reports·2023
Same author

TEMPORARY REMOVAL: VP.47 Interleukin 31 (IL-31) inhibition as a trigger for an immune-mediated myopathy?

Neuromuscular disorders : NMD·2022
Same author

Current production by non-methanotrophic bacteria enriched from an anaerobic methane-oxidizing microbial community.

Biofilm·2021
Same author

[Pain management in rare diseases].

Schmerz (Berlin, Germany)·2020
Same author

A 192-heme electron transfer network in the hydrazine dehydrogenase complex.

Science advances·2019
Same journal

Erratum to: Immunotherapeutic Approach to Cancer with Cutaneous DNA Vaccination.

Methods in molecular medicine·2015
Same journal

Methods for cancer gene therapy using tumor suppressor genes.

Methods in molecular medicine·2014
Same journal

Suppression of the human carcinoma phenotype by an antioncogene ribozyme.

Methods in molecular medicine·2014
Same journal

Methods for the use of stromal cells for therapeutic gene therapy.

Methods in molecular medicine·2014
Same journal

Methods for adenovirus-mediated gene transfer to synovium in vivo.

Methods in molecular medicine·2014
Same journal

Methods for gene transfer to synovium.

Methods in molecular medicine·2014
See all related articles

Related Experiment Video

Updated: Jun 3, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

DNA-Based Vaccination Primes Tumor-Rejecting T-Cell Responses.

W Böhm1, M Schleef, S Thoma

  • 1Institute of Medical Microbiology and Immunology, Universität Ulm, Ulm (Donau), Germany.

Methods in Molecular Medicine
|March 5, 2011
PubMed
Summary
This summary is machine-generated.

DNA vaccination effectively activates T-cell responses against various antigens. This approach shows promise for controlling tumor growth, particularly through cytotoxic T lymphocytes (CTLs).

More Related Videos

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Related Experiment Videos

Last Updated: Jun 3, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Area of Science:

  • Immunology
  • Vaccinology
  • Cancer Research

Background:

  • DNA-based vaccination is a potent method for inducing T-cell immunity.
  • T-cell responses, including CD4+ and CD8+ T-cells, are crucial for controlling intracellular pathogens and tumors.
  • Tumor rejection can be mediated by MHC-I restricted cytotoxic T lymphocytes (CTLs).

Purpose of the Study:

  • To explore the capacity of DNA vaccination to prime MHC-restricted T-cell responses.
  • To investigate the potential of T-cell responses induced by DNA vaccination in controlling tumor growth.
  • To highlight the role of CTLs in tumor rejection mediated by DNA vaccination.

Main Methods:

  • Utilizing DNA-based vaccination strategies to deliver protein antigens.
  • Analyzing MHC-II restricted CD4+ T-cell and MHC-I restricted CD8+ T-cell responses.
  • Evaluating T-cell effector functions against tumor cells expressing tumor-associated antigens (TAA) or viral antigens.

Main Results:

  • DNA vaccination efficiently primes both MHC-II restricted CD4+ and MHC-I restricted CD8+ T-cell responses.
  • These T-cell responses are effective against a range of epitopes, including immunodominant and subdominant ones.
  • MHC-I restricted CTLs induced by DNA vaccination can reject tumors expressing specific antigens.

Conclusions:

  • DNA vaccination is a versatile platform for generating robust T-cell immunity.
  • The induction of CTL responses via DNA vaccination holds significant potential for cancer immunotherapy.
  • Targeting tumor-associated antigens or viral antigens through DNA vaccination can lead to effective tumor control.